Abemaciclib Plus Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Premenopausal Women: Subgroup Analysis From the MONARCH 2 Trial
Patrick Neven(KU Leuven), George W. Sledge(Caris Life Sciences (United States)), Peter A. Kaufman(University of Vermont), Nadine Haddad(Eli Lilly (United States)), Sara M. Tolaney(Harvard University), Karla Hurt(Eli Lilly (United States)), Hiroji Iwata(Nagoya City University), Hope S. Rugo(City of Hope), Masakazu Toi(Mukogawa Women's University), Yi Lu(Shandong Provincial Hospital), Matthew P. Goetz(Mayo Clinic)
Cited by 4
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k